ISB Co-founder Dr. Lee Hood hosted a fireside chat with NIH Director Dr. Francis Collins. The renowned scientists talked about their early careers and long friendship, the challenge of COVID-19, the preceding scientific work that led to the fast development of COVID vaccines, and much more.
The multi-year Coaching for Cognition in Alzheimer’s (COCOA) clinical trial is nearly complete. The trial examined diet, exercise and cognitive training as possible non-pharmacological interventions to Alzheimer’s, with some trial members receiving telephonic coaching centered on stress, diet and exercise, as well as brain training focusing on brain speed and attention.
The impact of Alzheimer’s Disease is staggering – 6 million Americans diagnosed, a financial toll of $600 billion annually, and no effective drug treatments. ISB Co-founder Dr. Lee Hood said the traditional approach isn’t working, and we need to think about it in brand new ways.
Dr. David Sinclair, a Harvard Medical School professor and New York Times bestselling author, was the guest of honor for the ISB-Town Hall Science Series on Thursday. He joined genomics pioneer and ISB Co-founder Dr. Lee Hood for a conversation that covered the very latest in aging research.
ISB’s research into the aging microbiome was featured in a story published by Anahad O’Connor for The New York Times titled “A Changing Gut Microbiome May Predict How Well You Age.” The research featured was published in Nature Metabolism by Drs. Tomasz Wilmanksi, Noa Rappaport, Sean Gibbons and Nathan Price.
ISB researchers and their collaborators looked at the electronic health records of nearly 630,000 patients who were tested for SARS-CoV-2, and found stark disparities in COVID-19 outcomes — odds of infection, hospitalization, and in-hospital mortality — between White and non-White minority racial and ethnic groups.
NIAID Director Dr. Anthony Fauci sat down for a conversation with ISB’s Dr. Lee Hood. The renowned scientists spoke about the importance of basic research, the extraordinary speed of COVID research, the efficacy of mRNA vaccines on COVID-19, lessons learned from the COVID-19 pandemic, and much more.
ISB researchers and their collaborators are looking beyond the one-drug, one-solution approach that has thus far failed in Alzheimer’s disease research. Instead, they are focusing on other promising research avenues, such as the possible role of the gut microbiome in dementia.